Dextromethorphan is used to temporarily relieve cough caused by the common cold, the flu, or other conditions. This medication is generally used to provide temporary, symptomatic relief for the dry, hacking, non-productive cough associated with minor irritations of the throat and bronchi. It is commonly applied in conditions like the common cold and flu, offering supportive therapeutic benefit that contributes to easing the overall symptom load of persistent, irritating coughs.

The therapeutic domain is relevant for managing disruptive cough patterns that create symptoms that interfere with daily functioning, such as a persistent cough at night or during periods of rest. The symptomatic relief provided may help address symptom clusters that may become intense or disruptive. The key conditions and symptoms it helps manage include the dry cough associated with upper respiratory infections, minor throat irritation, and episodic coughing fits.

“The symptomatic relief provided supports patients during difficult episodes by contributing to easing the overall symptom load and supports general well-being.”

This relief provides supportive assistance when symptoms interfere with routine activities and helps patients cope more steadily with symptom fluctuations during acute, self-limiting symptomatic episodes.

Quick Fact: Relief for Dry, Hacking Cough
Primary Symptom Targeted	Irritative, Non-Productive Cough
Typical Context of Use	Acute self-limiting respiratory illnesses (cold/flu)
Core Patient Benefit	Supports comfort and supports quality of rest during symptomatic periods

Regulatory References

1. NIH MedlinePlus Drug Information

Official Eligibility Rules

Regulatory authorities define strict population rules for using Robitussin Antitussicum (Dextromethorphan). Use is generally approved for adults and children 12 years and over. Eligibility is determined by age, medical conditions, and concurrent medications, focusing solely on official regulatory guidance.

---

Contraindicated Populations (Must Not Use)

The medicine is contraindicated and must not be used by several patient groups, as specified in the product label:

• Age: Children under 12 years of age.
• Medication Status: Patients taking MAOIs or certain prescription medications for depression, such as SSRIs, or within 14 days of stopping MAOI treatment.
• Comorbidities: Individuals with, or at risk of, respiratory failure, including acute asthma attacks, or those with known hypersensitivity to the active ingredient.

---

Restricted or Conditional Use

Use is limited and requires medical consultation for specific physiological states:

• Organ Function: Patients with severe renal or hepatic impairment.
• Chronic Cough: Individuals with a chronic cough due to conditions like smoking or emphysema, or a cough producing excessive secretions, should only use this medicine under medical supervision.
• Reproductive Status: Safe use during pregnancy is not established; use during lactation is generally restricted to when considered essential by a physician.

The official regulatory profile for Dextromethorphan Hydrobromide establishes specific restrictions for co-use with other medicinal products and substances. This information is classified based on the nature of the documented interaction.

Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a contraindication documented in regulatory materials, including those prescribed for depression or Parkinson's disease. This restriction is based on the significant, official risk of developing Serotonin Syndrome [1.1]. A mandatory 14-day washout period must elapse after discontinuing MAOI therapy before this product can be administered [1.2].

Pharmacokinetic and Pharmacodynamic Interactions

The primary pharmacokinetic interaction is through the CYP2D6 enzyme system, which metabolizes Dextromethorphan. Co-use with potent CYP2D6 inhibitors (e.g., quinidine, fluoxetine, paroxetine, terbinafine) is noted to increase the systemic exposure and plasma concentrations of Dextromethorphan, which raises the risk of toxic effects [1.1].

A pharmacodynamic interaction is documented with other serotonergic agents (e.g., SSRIs, TCAs), as co-use increases the risk of Serotonin Syndrome due to additive effects. Additive Central Nervous System (CNS) depressant effects are also noted when co-administered with alcohol or other CNS depressants [1.1].

Interaction-related restrictions also formally apply to substances such as Grapefruit Juice and the herbal product St. John's Wort [1.6]. Caution is also noted for patients with documented severe hepatic impairment and those identified as poor CYP2D6 metabolizers, as they may naturally experience prolonged effects [1.1].

How Robitussin Antitussicum Works

Robitussin Antitussicum contains dextromethorphan (DXM), a pharmacologically active substance that operates primarily within the central nervous system to modulate the cough reflex arc. The mechanism of action is defined by two key mechanistic domains.

Central Cough Reflex Suppression

DXM exerts its main effect by acting within the cough center, a neural area situated in the medulla oblongata of the brainstem. This central engagement results in an elevation of the cough threshold, which is the required intensity of afferent sensory input needed to trigger the efferent motor response. This action increases the energy necessary to initiate the physical coughing action.

---

Sigma-1 Receptor Modulation

Additionally, DXM functions as a non-competitive agonist at the sigma-1 receptor (S1R), an intracellular chaperone protein located primarily on the endoplasmic reticulum of neurons. This specific molecular interaction influences calcium signaling, neurotransmitter release, and pathways regulating neuronal excitability. The resulting pathway effect contributes to the overall modulation of signal transmission within the medullary cough circuit.

Administration Guidelines

Robitussin Antitussicum, which contains Dextromethorphan Hydrobromide, is intended for oral administration across all its immediate-release dosage forms, including syrups and capsules. The usage regimen is based on fixed-interval schedules to maintain symptomatic control.

For adults and children aged 12 years and over, the standard dosage involves taking 10 mg to 20 mg every four hours, or 30 mg every six to eight hours. The absolute maximum daily intake must not exceed 120 mg in a 24-hour period.

Administration and Timing

The administration protocol for liquid forms mandates the product be shaken well and measured exclusively with the calibrated dosing device supplied to ensure dose accuracy. The medicine may be taken with or without food. Use is generally intended for short, temporary courses of treatment.

Instructions also define specific constraints for younger populations. For children between 6 and 12 years of age, a reduced maximum daily dose of 60 mg is applied, and the product is not recommended for use in children under 6 years of age. In the event a dose is missed, the user should skip that dose if the time for the next scheduled dose is near, rather than attempting to double the subsequent dose.

Recent Clinical Evidence: Dextromethorphan

Clinical evidence regarding dextromethorphan (DXM), the active ingredient in Robitussin Antitussicum, primarily focuses on its use as a cough suppressant.

---

Mechanism and Preclinical Research

Research explored the drug's properties in preclinical models, primarily focusing on its activity in the brain stem's cough center. Studies examined the drug's molecular activity and subsequent biological responses in lab settings relevant to cough reflex suppression. Clinical research generally assesses changes in cough frequency and severity following administration.

Clinical Efficacy Studies

Studies evaluating the use of DXM in individuals with acute, nonproductive cough often involve randomized, placebo-controlled designs. These trials documented whether the drug was associated with changes in cough frequency and intensity compared to baseline.

• Trial findings across different studies have been mixed regarding the magnitude and consistency of the antitussive effect. Some studies reported statistically significant reductions in cough frequency, while others noted minimal or no difference compared to placebo.
• Study exclusion criteria generally documented participants with chronic cough conditions, such as those related to asthma or chronic obstructive pulmonary disease (COPD).

Safety and Tolerability

Observed side effects were documented in clinical trials across various DXM formulations. Studies documented the occurrence and nature of commonly reported minor side effects.

• Common events reported in clinical settings included mild dizziness, drowsiness, and temporary gastrointestinal discomfort (e.g., nausea or stomach upset).
• The majority of observed side effects were classified as mild or moderate in severity. Serious adverse events were rarely reported and fully documented when they occurred.

Conclusion of Evidence Review

The overall body of research provides data supporting the investigation of dextromethorphan in the temporary relief of cough symptoms. Data regarding its efficacy may vary depending on the type of cough and specific study design.

Key Studies & References

1. Dextromethorphan (Monograph) - U.S. National Library of Medicine: DailyMed

Common questions about Robitussin Antitussicum (FAQ)

Q: How quickly does the cough-suppressing effect of Robitussin Antitussicum usually begin?

Official product information states that the antitussive effect typically begins relatively quickly after administration. The cough-suppressing action is expected to start within 15 to 30 minutes after taking the medicine by mouth.

---

Q: What is the typical duration of action for one dose of this medicine?

The cough-suppressing effect for standard immediate-release formulas typically lasts for approximately 3 to 6 hours after a person takes it orally. Regulatory documents describe the duration of effect as lasting approximately 3 to 6 hours.

---

Q: Are there any documented effects on a person's mood or alertness?

Official product documents list possible effects on the Central Nervous System (CNS). These include common effects such as drowsiness, dizziness, and confusion. In rare instances, more severe central effects like hallucinations or psychotic episodes have been documented.

---

Q: Is it common to feel restless or hyperactive as an adverse reaction?

The official literature indicates that symptoms of unusual excitement, nervousness, restlessness, or irritability may occur. These effects are generally associated with cases of overdose, rather than typical therapeutic use.

---

Q: Are there known effects of this medicine on sleep patterns?

The most common effect on sleep documented in official sources is drowsiness or somnolence. In rare instances, some regulatory information reports symptoms of unusual excitement or nervousness that could potentially interfere with normal sleep patterns.

---

Q: What does the official documentation state about driving or operating machinery while using this product?

Due to the potential for side effects like dizziness and drowsiness, official labeling generally suggests caution. The documentation indicates avoidance of activities that require high mental alertness, such as driving or operating heavy machinery, until a person is certain how the drug affects them.

---

Q: Is there a safety classification regarding the use of this medicine by older adults?

While the standard adult use applies to the older adult population, regulatory documents note that use in older adults may require a dosage at the lower end of the recommended range. This is noted due to the potential for increased sensitivity to the drug and higher susceptibility to side effects like dizziness or confusion.

---

Q: Is Robitussin Antitussicum known to cause dependence or withdrawal symptoms?

Official labeling for the active ingredient notes that it has the potential for abuse when used in doses far greater than recommended for cough relief. In cases of long-term misuse, regulatory documents have noted that psychological and physical withdrawal effects can occur upon abrupt cessation.

---

Q: What are the signs of excessive use of this drug?

Signs of excessive use or overdose, as documented in regulatory information, can affect the body and the mind. These may include blurred vision, severe nausea or vomiting, confusion, or unusual excitement or restlessness. In the most severe cases, symptoms such as slowed breathing or a state of psychosis or coma have been reported.

---

Q: Does this medicine interact with commonly used herbal supplements?

Regulatory product labels specifically caution against co-administration with St. John's Wort, as this can increase the risk of adverse effects. Official documents do not universally standardize information on every other herbal supplement.

---

Q: Is this medicine described as safe for people with high blood pressure?

Official labeling suggests consultation with a healthcare professional before use for individuals with high blood pressure. This is a general precaution documented in regulatory materials, indicating a need for caution or medical supervision with this population.

---

Q: Does taking this medicine with food change the time it takes to start working?

According to the official administration protocol, the medicine may be taken with or without food. However, regulatory labeling does not provide explicit data to quantify whether food intake alters the amount of time required for the cough-suppressant effect to begin.

---

Q: Can people with diabetes use this medicine, considering its ingredients?

Official labeling provides a list of both active and inactive ingredients. Some formulations may be sugar-free, while others, like syrups, may contain substances such as high fructose corn syrup. The suitability of a specific formulation for people with diabetes depends on the full list of inactive ingredients.

---

Q: Are there different strengths or concentrations available for purchase?

Regulatory documentation specifies different approved dosing schedules for the medicine's active ingredient. This implies that different commercially available product concentrations or formulations exist in the market to meet these varying dosage requirements.

---

Q: Why is the active ingredient sometimes a concern in certain types of drug screening?

High doses of the active ingredient in Robitussin Antitussicum may cause an issue with certain tests. Official documentation notes that the presence of the ingredient or its metabolites may lead to a false-positive result for other substances, such as PCP or opiates, on some drug screenings.

Storage and Disposal of Robitussin Antitussicum

The official labeling for Robitussin Antitussicum (dextromethorphan/guaifenesin liquid) strictly defines its storage and handling requirements. The medication must be kept at Controlled Room Temperature, which is specified as 20 C to 25 C (68 F to 77 F). It is explicitly required that the product Do not refrigerate to maintain stability.

Required Conditions

• Temperature: Store between 20 C and 25 C.
• Child Safety: It is mandatory to Keep out of reach of children to prevent accidental ingestion.

Disposal

Unused or expired product should not be flushed down the toilet. Disposal must follow regulatory guidelines, such as the FDA-recommended method for non-flushable medicines. This involves mixing the liquid with an unappealing substance, like coffee grounds or dirt, and then sealing the mixture in a container before placing it in the household trash.